- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:47 | TRANSTHERA-B Plans to Repurchase Up to RMB100M of H Shares | 1 | AASTOCKS | ||
| Di | HSI Reverts Down 268 pts Midday; HSBC HOLDINGS Sets New High Against Mkt; BABA-W Loses 'Red-Chip' Status; TRANSTHERA-B Plunges 58% | 27 | AASTOCKS | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE STRATEGY COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln | |||||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 18 JUNE 2026; (2) CHANGE OF THE INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION ... | - | HKEx | ||
| 18.06. | TRANSTHERA-B (02617): (1) POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 18 JUNE 2026; (2) ADOPTION OF THE H SHARE AWARD SCHEME; AND (3) AUTHORIZATION ... | 1 | HKEx | ||
| 12.06. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF OPERATING OFFICER | 1 | HKEx | ||
| 27.05. | TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 27.05. | TRANSTHERA-B (02617): COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE | - | HKEx | ||
| 26.05. | TRANSTHERA-B (02617): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, 18 JUNE 2026 AT 10:30 A.M. | - | HKEx | ||
| 26.05. | TRANSTHERA-B (02617): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 26.05. | TRANSTHERA-B (02617): CIRCULAR OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 26.05. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PHASE II CLINICAL TRIAL APPROVAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONE THERAPY FOR THE TREATMENT ... | - | HKEx | ||
| 26.05. | TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT TRANSTHERA SCIENCES (NANJING), INC. AND SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. ANNOUNCE A COLLABORATION ... | 1 | HKEx | ||
| 22.05. | TRANSTHERA-B (02617): RULES RELATING TO THE 2026 H SHARE AWARD SCHEME | - | HKEx | ||
| 22.05. | TRANSTHERA-B (02617): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON 18 JUNE 2026 OR ANY ADJOURNMENT THEREOF | - | HKEx |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,66 | +0,08 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 349,93 | +6,75 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 32,550 | +3,43 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| QIAGEN | 34,570 | +0,14 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 38 auf 40 Euro angehoben und die Einstufung auf "Kaufen" belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| VERA THERAPEUTICS | 43,130 | +1,58 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 109,43 | +1,21 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| ERASCA | 18,290 | +14,24 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,740 | +1,68 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,340 | -0,37 % | Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline | ||
| MINERALYS THERAPEUTICS | 26,880 | +0,75 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 62,41 | +5,42 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| ABSCI | 11,345 | +4,18 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,310 | +2,14 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| RELAY THERAPEUTICS | 19,740 | +6,36 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,950 | +0,40 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
Das Unternehmen TRANSTHERA SCIENCES NANJING INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSTHERA SCIENCES NANJING INC finden Sie auf Wallstreet Online.